Article

Topcon PASCAL Synthesis laser gets 510(k) clearance

Topcon Medical Laser Systems has received FDA 510(k) clearance for its portable, dual-port, pattern-scanning laser (PASCAL Synthesis).

Santa Clara, CA-Topcon Medical Laser Systems has received FDA 510(k) clearance for its portable, dual-port, pattern-scanning laser (PASCAL Synthesis).

Available in either 532- or 577-nm wavelengths, the device will allow fast and effective treatment of retinal disorders using clinically proven PASCAL technology, while offering physicians the option of keeping their current slit lamp set-up, the company said in a prepared statement. The laser is designed to integrate with Topcon D7 and Haag-Streit style-slit lamps.

“The introduction of the PASCAL Synthesis will, for the first time, offer physicians a more cost-effective solution in providing their patients pattern-scanning laser technology,” said Tom Koike, president and chief executive officer at Topcon. “And with Endpoint Management available as an upgrade on all Synthesis lasers, physicians will have the option to treat at sub-threshold levels for less-damaging treatment of a variety of retinal diseases.”

The marriage of these two technologies allows for greater control, efficiency, and precision, resulting in positive therapeutic outcomes at non-damaging treatment levels.

“It is an additional step toward offering customers new and improved technologies that not only complement their laser treatment portfolio, but provide greater clinical benefits for their patients,” Koike added.

For more articles in this issue of Ophthalmology Times eReport, click here.

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.